Lisocabtagene maraleucel治疗复发或难治性边缘区淋巴瘤:TRANSCEND FL 2期研究主要分析
TRANSCEND FL研究MZL队列评估CD19 CAR-T疗法liso-cel,纳入77例经至少二线系统治疗的复发/难治性MZL患者,67例接受治疗,66例可评估疗效。
要点
- liso-cel在复发/难治性MZL中总缓解率达95%,达到主要终点。
- 3级细胞因子释放综合征或神经事件各占4%,无4-5级事件。
- ≥3级感染占16%,安全谱可控且无新安全信号。
核心结论
- liso-cel在复发/难治性MZL中显示高比例持久缓解,安全性可控,支持其作为新的治疗选择。
研究设计与样本
- 全球多中心、单臂、多队列2期研究,纳入美国、加拿大、欧洲和日本30个中心的复发/难治性MZL患者。
- 患者需至少接受过两线系统治疗,接受liso-cel(100×10^6 CAR+ T细胞)输注,允许桥接治疗。
- 主要终点为独立评审委员会按Lugano 2014标准评估的总缓解率(无效假设≤50%)。
主要发现
- 77例白细胞采集患者中67例接受liso-cel,66例可评估疗效。
- 亚型分布:结节型32例(48%)、脾型18例(27%)、结外MALT型17例(25%);中位既往系统治疗线数为3(IQR 2-4)。
- 所有患者均发生治疗相关不良事件;3级细胞因子释放综合征和神经事件各3例(4%),无4-5级事件。
- ≥3级感染11例(16%):治疗期90天内6例(9%),治疗后7例(10%)。
关键数值与推荐
- 3级细胞因子释放综合征或神经事件各3例(4%),无4-5级事件。
- ≥3级感染11例(16%),其中治疗期90天内6例(9%),治疗后7例(10%)。
临床怎么用
- liso-cel可作为经至少二线系统治疗的复发/难治性MZL患者的新治疗选择。
- 治疗期间需监测细胞因子释放综合征、神经事件和感染,但安全性总体可控。
局限性
- 单臂设计,无随机对照。
- 样本量有限(67例接受治疗,66例可评估疗效)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Effective treatments with deep and durable responses for relapsed or refractory marginal zone lymphoma (MZL) are lacking. The objective of the primary analysis from the MZL cohort of TRANSCEND FL was to evaluate the efficacy and safety of the CD19-directed chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel. METHODS: In this phase 2, single-arm, multicohort study, patients from 30 sites in the USA, Canada, Europe, and Japan with relapsed or refractory MZL who had at least two previous lines of systemic therapy were eligible to receive lisocabtagene maraleucel (100 × 106 CAR+ T cells). Bridging therapy was allowed. The primary endpoint was overall response rate per independent review committee by CT by use of Lugano 2014 criteria (null hypothesis ≤50%). This study is registered with ClinicalTrials.gov, NCT04245839, and is ongoing. FINDINGS: Of 77 leukapheresed patients recruited between November 11, 2020, and August 24, 2023, 67 received lisocabtagene maraleucel and 66 were efficacy evaluable. MZL subtypes included nodal (n=32 [48%]), splenic (n=18 [27%]), and extranodal-mucosa-associated lymphoid tissue (n=17 [25%]). Median (IQR) previous lines of systemic therapy was 3 (2-4). Median on-study follow-up was 24·1 months. The primary endpoint was met, with an overall response rate of 95% (n=63; 95% CI, 87·3-99·1; one-sided p<0·0001). All patients experienced a treatment-related adverse event. Grade 3 cytokine release syndrome or neurological events occurred in three (4%) patients each (no grade 4-5 events). 11 (16%) patients had grade ≥3 infections: six (9%) patients during the 90-day treatment-emergent period and seven (10%) during the post-treatment-emergent period. INTERPRETATION: In patients with relapsed or refractory MZL, lisocabtagene maraleucel showed high rates of durable responses. The safety profile was manageable, with no new safety signals. These results support lisocabtagene maraleucel as a new treatment option for patients with relapsed or refractory MZL. FUNDING: Celgene, a Bristol-Myers Squibb Company.
引用
- Palomba ML, Schuster SJ, Karmali R, et al. Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study. Lancet. 2026. PMID: 41692020. doi:10.1016/S0140-6736(25)02435-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。